Protein conjugates capsular polysaccharides

Haemophilus influenzae type b Cultures of H. influenzae type b 1 Separation of capsular polysaccharide 2 Conjugation with a protein Estimation of capsular polysaccharide content ... 

Purified capsular polysaccharide of H. influenzae type b (usually linked to a protein carrier, forming a conjugated vaccine)... 

A further type of vaccine included in the subunit category is the capsular polysaccharide vaccines, for example, those against Haemophilus influenzae and meningococcal meningitis. In this case an extract of the polysaccharide outer capsule of the bacterium is used as a vaccine and is sometimes conjugated to protein to... 

Haemophilus b conjugate vaccine contains 25 micrograms of a purified capsular polysaccharide and 18 micrograms of diphtheria toxoid protein in a single dose of 0.5 mL. How many micrograms of diphtheria toxoid proteins are there in a vial containing 2.5 mL of the vaccine ... 

J. A. Johnson, A. Joseph, and J. G. Morris, Capsular polysaccharide-protein conjugate vaccines against Vibrio cholerae 0139 Bengal, Bull. Inst. Pasteur, 93 (1995) 285-290. 

Protein Conjugates of Oligosaccharide Fragments of Capsular Polysaccharides... 

It has been possible to produce vaccines to use for immunization against certain bacterial infections and other human diseases. Staphylococcus aureus capsular polysaccharide in combination with a carrier protein has been used to prepare monovalent vaccines specific for S. aureus [86], The vaccine was administered to groups of healthy adults and to patients with end-stage renal disease. The antibodies are directed at the polysaccharide moiety of the glycoconjugate. The data of this study show that conjugate-induced antibodies to S. aureus can provide partial protection against S. aureus bacteremia, Fig. (45). 

Capsular polysaccharide of bacteria is one of the significant targets for development of vaccines [128]. For example, Haemophilus influenza type B (Hib) vaccine, made of a polysaccharide-protein conjugate, is now used worldwide as a highly effective therapy [129]. Verez-... 

Capsular polysaccharides (CPS) and lipopolysaccharides from bacteria are employed for the production of vaccines against human diseases. Initial development of CPS as a vaccine was followed by the development and introduction of conjugate polysaccharide-protein vaccines. The principles leading to both developments are reviewed. 

The field is actually in a good position to contribute to the development of bacterial polysaccharide glycoconjugate vaccines. Numerous fragments of capsular polysaccharides, lipopolysaccharides, or other bacterial carbohydrates have been synthesized and their protein conjugates obtained [87]. 

Contains 5 meg 0.5 ml HBsAg and 7.5 meg Haemophilus influenzae type B purified capsular polysaccharide fragments conjugated to 125 meg Neisseria meningitidisouler membrane protein complex. 

Four different vaccines for Hib are licensed in the United States. All these vaccines are composed of Hib capsular polysaccharide conjugated to a protein carrier. All four vaccines use a different carrier. Polyribosyl ribitol phosphate (PRP) capsule is an important virulence factor that renders Hib resistant to phagocytosis by neutrophils in the absence of specific anti-capsular antibody. Antibody directed against PRP capsule of Hib is primarily responsible for host resistance to infection. The Hib vaccine is composed of the purified, capsular polysaccharide of Hib. Antibodies to this antigen correlate with protection against invasive disease. 

---